Latest news
Five Synexus® sites randomise more than 1300 patients in three weeks
Synexus® recently randomised more than 1300 patients in a vaccine study at five sites across Europe over a three week period, as part of a global programme.
Visit our patients site
At Synexus we produce great results. For our clients, the pharmaceutical companies we partner, the healthcare professionals and of course, for our patients.